Ä¢¹½ÊÓƵAPP

Jason Gardner joined Ä¢¹½ÊÓƵAPP in 2023 as CEO-Partner and CEO of Ampersand Biomedicines.

Jason has over two decades of leadership experience across pharmaceutical and biotechnology companies, with deep expertise in drug discovery and development, and a successful track record in securing strategic partnerships, scaling companies, and building teams. He was most recently the CEO, President, and Co-Founder of Magenta Therapeutics. At Magenta, he led the company as it advanced key programs into the clinic, completed a successful IPO, and scaled to more than 100 employees.

Prior to his role at Magenta, he held multiple positions of increasing responsibility at GSK, including serving as the head of Research & Development in Boston, creating and leading the Regenerative Medicine Unit, and establishing partnerships with Harvard’s Stem Cell Institute and The Telethon Institute for Gene Therapy. In addition, Jason was head of the Center of Excellence for External Drug Discovery at GSK, where he led a team that oversaw more than 40 programs across five therapeutic areas. Prior to GSK, Jason was Associate Director at Progenics Pharmaceuticals and a Principal Scientist at Chiron Corporation.

Jason holds a B.A. and M.A. in Natural Sciences (Biochemistry) from Cambridge University and a D.Phil. in Molecular Medicine from Oxford University. He completed a postdoctoral fellowship studying hematopoietic stem cells at Harvard Medical School.